Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
This study will determine the efficacy, safety, and tolerability of a 40 milligrams (mg)
 once-daily (QD) dose of LY2940094 for 8 weeks in participants with MDD.
Inclusion Criteria:

 -  Have a diagnosis of MDD without psychotic features as defined in the Diagnostic and
 Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

 -  Have clinically significant depressive symptoms defined by a GRID Hamilton Depression
 Rating Scale 17 (HAMD17) Total Score ≥20 at screening

 -  Body mass index (BMI) between 18 and 35 kilogram per square meter (kg/m²)

 Exclusion Criteria:

 -  Have a current or previous diagnosis of bipolar I or II disorder, MDD with psychotic
 features, schizoaffective disorder, schizophrenia, or other psychotic disorder

 -  Currently meeting the criteria of treatment-resistant depression defined as ≥2
 documented, failed treatment trials of adequate dose and duration with a registered
 antidepressant during the current depressive episode

 -  Had electroconvulsive treatment, transcranial magnetic stimulation, vagal nerve
 stimulation for symptoms of depression in the 6 months prior to screening

 -  Have any clinically significant medical or uncontrolled condition or circumstance
 prior to randomization that could affect participant safety